ClinicalTrials.gg
CompletedNCT02256423Updated Oct 3, 2014

A Study Comparing Three Formulations of Ibuprofen in Healthy Subjects

A Phase 1 interventional study of REFERENCE 1: Nurofen® 200 mg tablet and REFERENCE 2: Ibuprofen 200 mg soft gel capsule in Healthy Volunteer Study, sponsored by Simbec Research. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-03.

Sponsored by Simbec Research · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This is an open-label, randomised, 3-period, 3-sequence single-dose crossover study to determine the comparative pharmacokinetic profile of the Test Investigational Medicinal Product (IMP) Ibuprofen 200 mg soft gel capsule (lipid formulation) with that from the reference products Nurofen® 200 mg tablet and ibuprofen 200 mg soft gel capsule following single dose administration in healthy male and female subjects.

The study comprises of a pre-study screen (within 14 days of the first dose), followed by 3 Treatment Periods (1, 2 and 3) and a post study follow up (3 - 7 days after the last dose). Each Treatment Period is of 1 day in duration, from the afternoon before dosing (Day -1) until 12 hours (h) post-dose (Evening of Day 1). Study drug is administered on the morning of Day 1 following an overnight fast. PK samples will be collected pre-dose and up to 12 h post-dose (x15 samples) for the measurement of ibuprofen. Safety is evaluated at specified times throughout the study. There is at least 48 h between dose administrations.

02

Conditions studied

  • Healthy Volunteer Study

Keywords

  • Ibuprofen
  • healthy volunteer study
  • pharmacokinetics
03

In context

Lead sponsor

Simbec Research is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy males and females between 18 and 50 years of age.
  2. Female subject of child bearing potential with a negative pregnancy test at the Screening Visit and willing to use an effective method of if applicable (unless of non- or where abstaining from sexual intercourse is in line with the preferred and usual lifestyle of the subject) from Day 1 until 3 months afterwards.
  3. Female subject of non-child bearing potential with negative pregnancy test at the Screening Visit. For the purposes of this study, this is defined as the subject being amenorrheic for at least 12 consecutive months or at least 4 months post-surgical sterilisation (including bilateral fallopian tube ligation or bilateral oophorectomy with or without hysterectomy). Menopausal status will be confirmed by demonstrating at screening that levels of follicle stimulating hormone (FSH) fall within the respective pathology reference range. In the event a subject's menopause status has been clearly established (for example, the subject indicates she has been amenorrheic for 10 years), but FSH levels are not consistent with a condition, determination of subject eligibility will be at the discretion of the Chief Investigator following consultation with the Sponsor's Responsible Physician.
  4. Subject with a (BMI) of 18-30 kilogram (kg)/metre square (m2). Body Mass Index = Body weight in kg / [Height in m]2.
  5. Subject with no abnormal serum biochemistry, haematology and urine examination values within 14 days of the first dose.
  6. Subject with a negative urinary drugs of abuse screen, determined within 14 days of the first dose (a positive alcohol result may be repeated at the discretion of the Investigator).
  7. Subject with negative (HIV), surface antigen (Hep B) and virus antibody (Hep C) results.
  8. Subject with no clinically significant abnormalities in 12-lead determined within 14 days of the first dose.
  9. Subject must be available to complete the study (including all follow up visits) and comply with study restrictions.
  10. Subject must satisfy a medical examiner about their fitness to participate in the study.
  11. Subject must provide written to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. History of allergy to NSAIDs or aspirin and history of peptic ulcer or gastrointestinal bleeding.
  2. A history of gastrointestinal disorder likely to influence drug absorption, such as Gastroesophageal reflux disease
  3. Receipt of regular medication within 14 days of the first dose that may have an impact on the safety and objectives of the study (at the Investigator's discretion).
  4. Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular or metabolic dysfunction.
  5. A clinically significant history of previous allergy / sensitivity to ibuprofen.
  6. A clinically significant history of drug or alcohol abuse.
  7. Inability to communicate well with the Investigator (i.e., language problem, poor mental development or impaired cerebral function).
  8. Participation in a New Chemical Entity clinical study within the previous 4 months or a marketed drug clinical study within the previous 3 months. (N.B. between studies is defined as the period of time elapsed between the last dose of the previous study and the first dose of the next study).
  9. Donation of 450 mL or more blood within the previous 3 months.
  10. Subjects who are current smokers, or those who have used nicotine products within the previous 3 months.
  11. Subject with positive (HIV), surface antigen (Hep B) and virus antibody (Hep C) results.
  12. Any subject who, in the judgment of the Investigator, is likely to be non-compliant with study procedures and/or restrictions during the study, or unable to cooperate because of a language problem or poor mental development.
  13. Subjects must not have taken over the counter drugs and herbal remedies and supplements should not be taken from 7 days prior to the first dose and throughout the duration of the study dosing periods.
  14. Prescribed drugs should not be taken for 7 days before the first dose and throughout the duration of the study dosing periods. This does not include the oral pill.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Active comparator
    REFERENCE 1: Nurofen® 200 mg tablet

    Single group 3-way crossover study

    Drug: REFERENCE 1: Nurofen® 200 mg tablet

  • Active comparator
    REFERENCE 2: Ibuprofen 200 mg soft gel capsule

    Single group 3-way crossover study

    Drug: REFERENCE 2: Ibuprofen 200 mg soft gel capsule

  • Experimental
    ibuprofen 200 mg soft gel capsule

    single group, 3-way cross

    Drug: ibuprofen 200 mg soft gel capsule

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics

    Maximum plasma concentration (Cmax), time to Cmax (tmax), elimination rate constant (λz), terminal half-life (t1/2), area under the concentration-time curve (AUC) from time of dosing to last measurable concentration (AUC0-t), partial area under plasma concentration time curve at the following nominal blood sampling time points 15min, 30min, 45min, 1h, 1.20h, 1.40h and 2h (AU0-n), AUC extrapolated to infinity (AUC0-∞), plasma clearance (CL/F), MRT (mean residence time) and AUC% extrapolated (residual area).

    Time frame: PK samples are taken up to 12 hours of each study period.

Secondary outcomes

  1. Safety

    AEs, vital signs (sitting blood pressure and pulse), ECG (heart rate, PR interval, QRS width, QT interval and QTcB interval) and laboratory (haematology, biochemistry and urinalysis) data.

    Time frame: participants will be followed for the duration of stay, an expected average of 3 weeks

07

Study locations

1 site
  • Simbec Research Limited
    Merthyr Tydfil, CF48 4DR, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2014, a primary completion of Aug 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2014
First posted
Oct 3, 2014
Start
Jul 2014
Primary completionActual
Aug 2014
CompletionActual
Aug 2014
Last update
Oct 3, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02256423
Lead sponsor
Simbec Research
Responsible party
Girish Sharma (Associate Medical Director, Simbec Research) — Principal investigator
First posted
Oct 3, 2014
Start date
Jul 2014
Primary completion
Aug 2014
Completion
Aug 2014
Last update
Oct 3, 2014

Study contacts

Girish Sharma, MBBS
principal investigator · Simbec Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuprofen

Start the discussion